Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Naxifylline
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Naxifylline is a chemical substance identified by its molecular formula C18H24N4O3 and molecular weight 344.41. It is classified as a purine derivative. While code names such as BG-9719, BG9719, and CVT-124 are associated with it, detailed information regarding its specific mechanism of action, primary indications, developers, or current development status is not publicly available in the provided sources.
- Other names
- 1H-PURINE-2,6-DIONE, 3,7-DIHYDRO-8-(3-OXATRICYCLO(3.2.1.0(SUP 2,4))OCT-6-YL)-1,3-DIPROPYL-, (1S-(1.ALPHA.,2.BETA.,4.BETA.,5.ALPHA.,6.ALPHA. ))-8-[(2S,5,6-exo)-5,6-epoxy-2-norbonyl]-1,3-dipropylxanthine
02
Targets
ADORA2A (Adenosine A₂A Receptor)PDE (Phosphodiesterase family)ADRB2 (β2)
Beyond the preview
Go deeper on Naxifylline.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Naxifylline.